Ads
related to: alpha protocol guide to cancer patients research and treatment- Side Effects
View Potential Side Effects While
Taking IMFINZI.
- Understand How It Works
Learn How IMFINZI Works
On The Official Site.
- What Is IMFINZI?
Learn About IMFINZI & See How It
Works On The Official Patient Site.
- Read FAQs
Have Questions About IMFINZI?
Get Answers Here.
- Official Patient Website
Learn More About IMFINZI As A
Possible Treatment Option.
- Sign Up For More Info
Register For More Information
And A Patient Starter Kit.
- Side Effects
Search results
Results From The WOW.Com Content Network
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. [1] It has the potential to provide highly targeted treatment, especially to microscopic tumour cells.
Alpha radiation is a nuclear phenomenon in which a heavy radionuclide emits an energetic alpha particle (consisting of two protons and two neutrons) and transmutes to a different radionuclide. The emitted alpha particle has a range in tissue of only 40-90 microns, which minimizes collateral damage when used for treatment purposes.
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
Long-term effects were also a concern, as patients were often cured and could expect long survival after chemotherapy. Infertility was a major long-term side effect, and even more seriously, the risk of developing treatment-related myelodysplasia or acute leukemia was increased up to 14-fold in patients who received MOPP. [14]
Immutep's first Phase I study of efti in cancer patients was an open-label study in 21 metastatic renal cell carcinoma patients, with the drug being used as a monotherapy. [5] These patients were known to be immunocompromised. The study, which began in late 2005, saw the patients administered ascending doses of efti (up to 30 mg per ...
Ad
related to: alpha protocol guide to cancer patients research and treatment